§ Dr. KumarTo ask the Secretary of State for Health how many responses were received by the Medicines Control Agency in response to the MLX 282 consultation document issued on 13 February; what percentage were in favour of the measures proposed; and how many and what percentage were from pharmaceutical companies. [53351]
864W
§ Ms BlearsMLX 282 is a consultation document on proposals from the European Commission to amend the body of EC legislation that regulates medicinal products for human use. The proposals for reform are wide-ranging.
MLX 282 was issued on 13 February 2002 by the Medicines Control Agency (MCA), inviting views, to 247 recipients including trade associations representing the pharmaceutical and related industries, practitioners' representative bodies and patient groups. Individual pharmaceutical companies were not approached. The formal consultation period ended on 10 May 2002.
An advertisement placed in a national daily newspaper on Tuesday 23 April has generated a number of identical e-mail responses expressing reservations about a possible increase in the regulation of the natural health therapies sector at the EU and national level. In addition the MCA has so far received 12 formal responses to the consultation. 9 of those focused on and opposed the possible increase in the regulation of the natural health therapies sector.